ILD Onset in MDA-5 Dermatomyositis | RheumNow
Anti–melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is a rare, aggressive and progressive subtype of DM. Its’ severity is dependent on the development of progressive interstitial lung disease (ILD), manifesting as either rapidly progressive ILD (RPILD) and chronic ILD (CILD). MDA-5+ RPILD carries a high mortality rate and defined by worsening dyspnea accompanied by radiographic changes within 3 months of pulmonary symptom onset. The reported study defines the time interval between ILD and MDA5+ DM diagnosis.